Examkin

Question

Difficulty: HardInfectious Diseases

A 58-year-old man is evaluated in the hospital on the third day of admission for a catheter-related bloodstream infection. He initially presented to the emergency department with fever, chills, and hypotension during his outpatient hemodialysis session. At admission, blood cultures were drawn, his tunneled hemodialysis catheter was removed, and he was started on empiric intravenous vancomycin and cefepime. His past medical history is notable for end-stage renal disease, hypertension, and type 2 diabetes mellitus. His medical record indicates an allergy to amoxicillin, which caused a diffuse, non-pruritic maculopapular rash 15 years ago. Today, the patient is afebrile and hemodynamically stable. The blood cultures drawn at admission are growing *Staphylococcus aureus*.

Susceptibility testing results are as follows:

AntimicrobialInterpretation
OxacillinSusceptible
CefazolinSusceptible
CefepimeSusceptible
VancomycinSusceptible
PenicillinResistant

Which of the following is the most appropriate next step in antibiotic management?

  1. Discontinue vancomycin and cefepime; start intravenous cefazolinAnswer
  2. B
    Discontinue cefepime and continue intravenous vancomycin
  3. C
    Discontinue vancomycin and continue intravenous cefepime
  4. D
    Discontinue vancomycin and cefepime; start intravenous daptomycin
  5. E
    Discontinue vancomycin and cefepime; start intravenous ceftaroline

Answer

Discontinue vancomycin and cefepime; start intravenous cefazolin
The patient has a bloodstream infection caused by methicillin-susceptible *Staphylococcus aureus* (MSSA), as demonstrated by the isolate's susceptibility to oxacillin and cefazolin. In cases of MSSA bacteremia, targeted therapy with a beta-lactam—such as a first-generation cephalosporin (cefazolin) or an antistaphylococcal penicillin (nafcillin, oxacillin)—is the standard of care. These agents are clinically superior to vancomycin for MSSA infections, demonstrating faster rates of bacterial clearance and reduced overall mortality. A common clinical challenge involves patients with a reported penicillin allergy. This patient experienced a delayed, non-pruritic maculopapular rash 15 years ago, which is a mild, non-IgE-mediated reaction. More importantly, cephalosporin cross-reactivity is driven largely by structural similarities in the R1 side chains. Cefazolin possesses a unique R1 side chain (a tetrazolyl-methyl group) that is not shared with amoxicillin, penicillin, or any other commonly used cephalosporin. As a result, cross-reactivity between amoxicillin and cefazolin is virtually non-existent. Discontinuing the broad-spectrum empiric regimen (vancomycin and cefepime) and initiating targeted intravenous cefazolin maximizes clinical efficacy while strictly adhering to antimicrobial stewardship principles.

Step-by-Step Solution

1
Identify the pathogen and its resistance profile.
The blood culture is growing methicillin-susceptible Staphylococcus aureus (MSSA), as indicated by susceptibility to oxacillin and cefazolin.
Pathogen identification dictates the shift from empiric to targeted antibiotic therapy.
2
Determine the optimal pharmacotherapy for MSSA bacteremia.
Targeted beta-lactam therapy (like cefazolin or nafcillin) is superior to vancomycin for MSSA bloodstream infections.
Beta-lactams provide faster bacterial clearance and are associated with lower mortality rates in MSSA bacteremia compared to vancomycin.
3
Evaluate the patient's reported beta-lactam allergy.
The patient had a non-pruritic maculopapular rash to amoxicillin 15 years ago, indicating a mild, non-IgE-mediated delayed hypersensitivity reaction rather than anaphylaxis.
Accurate allergy assessment prevents unnecessary avoidance of first-line therapies.
4
Select the specific agent based on cross-reactivity and stewardship principles.
Intravenous cefazolin should be initiated.
Cefazolin has a unique R1 side chain that does not cross-react with penicillins or amoxicillin. It provides narrow-spectrum, highly effective coverage for MSSA, adhering to strict antibiotic stewardship guidelines.

Key Concept

Targeted therapy for MSSA bacteremia and beta-lactam cross-reactivity principles
Rate this question

Topics

Infectious Diseases

More questions from this topic